[go: up one dir, main page]

WO2014026189A3 - Production et utilisation d'un nouveau médicament anticancéreux en thérapie - Google Patents

Production et utilisation d'un nouveau médicament anticancéreux en thérapie Download PDF

Info

Publication number
WO2014026189A3
WO2014026189A3 PCT/US2013/054530 US2013054530W WO2014026189A3 WO 2014026189 A3 WO2014026189 A3 WO 2014026189A3 US 2013054530 W US2013054530 W US 2013054530W WO 2014026189 A3 WO2014026189 A3 WO 2014026189A3
Authority
WO
WIPO (PCT)
Prior art keywords
mirna
mir
cells
human
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/054530
Other languages
English (en)
Other versions
WO2014026189A2 (fr
WO2014026189A4 (fr
Inventor
Shi-Lung Lin
David TS WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/572,263 external-priority patent/US20130210120A1/en
Application filed by Individual filed Critical Individual
Priority to CN201380042546.7A priority Critical patent/CN105143459B/zh
Priority to EP13827192.9A priority patent/EP2882859A4/fr
Priority to JP2015526754A priority patent/JP2015530988A/ja
Publication of WO2014026189A2 publication Critical patent/WO2014026189A2/fr
Publication of WO2014026189A3 publication Critical patent/WO2014026189A3/fr
Publication of WO2014026189A4 publication Critical patent/WO2014026189A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne en général une conception et un procédé de développement de nouveaux médicaments, vaccins et thérapies anti-tumoraux et/ou anticancéreux, à l'aide d'un microARN et/ou de ses homologues/mimétiques/dérivés ARNsh. Plus particulièrement, la présente invention concerne une utilisation d'une composition de précurseur de miARN produit par un procaryote (pro-miARN) pouvant être administrée dans des cellules humaines et transformée par les cellules en effecteurs miARN matures pour susciter des effets interférents spécifiques sur des gènes ciblés par mir-302, conduisant ultérieurement à un résultat bénéfique de suppression tumorale et de thérapie anticancéreuse. Les cellules procaryotes n'expriment pas naturellement ou ne transforment pas naturellement les précurseurs de miARN eucaryotes (pré-miARN), alors que la présente invention concerne également un procédé inductible pour l'expression de pre-miARN, en particulier des précurseurs de mir-302, par l'utilisation du système de transcription procaryote. Puisque mir-302 est un suppresseur de tumeur connu chez l'être humain, cette nouvelle découverte avance la conception et le procédé de développement de nouveaux médicaments, vaccins et thérapies anticancéreux dirigés contre de multiples sortes de tumeurs et de cancers humains.
PCT/US2013/054530 2012-08-10 2013-08-12 Production et utilisation d'un nouveau médicament anticancéreux en thérapie Ceased WO2014026189A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201380042546.7A CN105143459B (zh) 2012-08-10 2013-08-12 新颖治疗用抗癌药的制造与使用
EP13827192.9A EP2882859A4 (fr) 2012-08-10 2013-08-12 Production et utilisation d'un nouveau médicament anticancéreux en thérapie
JP2015526754A JP2015530988A (ja) 2012-08-10 2013-08-12 新規な治療用抗癌薬の製造及び使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13/572,263 US20130210120A1 (en) 2011-08-12 2012-08-10 Inducible Gene Expression Composition for Using Eukaryotic Pol-2 Promoter-Driven Transcription in Prokaryotes and the Applications Thereof
US13/572,263 2012-08-10
US201261746786P 2012-12-28 2012-12-28
US61/746,786 2012-12-28
US201361761890P 2013-02-07 2013-02-07
US61/761,890 2013-02-07

Publications (3)

Publication Number Publication Date
WO2014026189A2 WO2014026189A2 (fr) 2014-02-13
WO2014026189A3 true WO2014026189A3 (fr) 2014-05-01
WO2014026189A4 WO2014026189A4 (fr) 2014-06-19

Family

ID=50068735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/054530 Ceased WO2014026189A2 (fr) 2012-08-10 2013-08-12 Production et utilisation d'un nouveau médicament anticancéreux en thérapie

Country Status (4)

Country Link
EP (1) EP2882859A4 (fr)
JP (3) JP2015530988A (fr)
CN (1) CN105143459B (fr)
WO (1) WO2014026189A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3384026A1 (fr) * 2015-12-02 2018-10-10 Shi-Lung Lin Utilisation de précurseurs de micro-arn comme médicaments permettant d'induire l'expansion de cellules souches adultes
WO2017204874A1 (fr) * 2016-05-27 2017-11-30 Shi-Lung Lin Composition et procédé d'utilisation de précurseurs de mir-302 comme médicaments anticancers afin de traiter le cancer du poumon humain
CN107913284B (zh) * 2016-10-09 2022-09-16 上海市东方医院 miRNA302-367簇的微小RNA在靶向抑制血管新生和肿瘤生长的应用
WO2022260718A1 (fr) * 2021-06-12 2022-12-15 Lin Shi Lung Nouvelle réaction de cyclage de réplicase (rcr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240126A1 (en) * 2008-05-07 2010-09-23 Shi-Lung Lin Development of universal cancer drugs and vaccines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970664B (zh) * 2008-01-16 2013-08-21 林希龙 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞
WO2013025248A1 (fr) * 2011-08-12 2013-02-21 Mello Biotechnology, Inc. Expression pouvant être induite à partir du promoteur eucaryote pol-2 chez des procaryotes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240126A1 (en) * 2008-05-07 2010-09-23 Shi-Lung Lin Development of universal cancer drugs and vaccines
WO2011025566A1 (fr) * 2009-08-26 2011-03-03 Shi-Lung Lin Développement de médicaments et vaccins universels contre le cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOTA, J ET AL.: "Therapeutic microRNA Delivery Suppresses Tumorigenesis In A Murine Liver Cancer Model.", CELL., vol. 137, 12 June 2009 (2009-06-12), pages 1005 - 1017, XP055004118 *
SIBLEY, CR ET AL.: "Novel RNA-Sased Strategies For Therapeutic Gene Silencing.", THE AMERICAN SOCIETY OF GENE & CELL THERAPY., vol. 18, 19 January 2010 (2010-01-19), pages 466 - 476, XP055004655 *

Also Published As

Publication number Publication date
JP2020037599A (ja) 2020-03-12
WO2014026189A2 (fr) 2014-02-13
CN105143459A (zh) 2015-12-09
WO2014026189A4 (fr) 2014-06-19
CN105143459B (zh) 2020-04-14
EP2882859A4 (fr) 2016-04-13
EP2882859A2 (fr) 2015-06-17
JP2015530988A (ja) 2015-10-29
JP2018016633A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
Parasramka et al. MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals
Anfossi et al. MicroRNAs, regulatory messengers inside and outside cancer cells
Garofalo et al. miR221/222 in cancer: their role in tumor progression and response to therapy
Yan et al. Non-coding RNAs in cancer stem cells
Sell et al. MicroRNAs in cancer metastasis: biological and therapeutic implications
Xu et al. microRNA regulation of human pancreatic cancer stem cells
WO2014117050A3 (fr) Arnmi modifié en tant qu'échafaudage pour de l'arnsh
NZ742420A (en) Individualized vaccines for cancer
WO2014026189A3 (fr) Production et utilisation d'un nouveau médicament anticancéreux en thérapie
EP4335502A3 (fr) Système promoteur u6 modifié pour expression spécifique de tissu
Matejuk et al. MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response
MX394276B (es) Inhalador de polvo seco y metodo de uso
Donzelli et al. MicroRNAs: non-coding fine tuners of receptor tyrosine kinase signalling in cancer
EP3777897A3 (fr) Porteurs pharmaceutiques contenant des miarn pour utilisation dans le traitement de maladies fibrotiques dues à l'hyperglycémie
WO2019213128A8 (fr) Compositions et méthodes thérapeutiques de délivrance de gènes de microarn
Huang et al. Construction of HCC-targeting artificial miRNAs using natural miRNA precursors
BR112012022946A2 (pt) método para proliferar cardiomiócitos usando micro-rna
AU2012325682A8 (en) Microalgal extraction
MX2016010177A (es) Composicion adyuvante anticancerosa que contiene promotor de la expresion de rip3 como principio activo, metodo para la deteccion de adyuvante anticanceroso que potencia la sensibilidad al farmaco anticanceroso mediante la estimulacion de la expresion de rip3 y metodo para controlar la sensibilidad del farmaco anticanceroso.
MX2013011694A (es) Analogos de taxano y abeo-taxanos.
WO2012135818A3 (fr) Diagnostics du cancer, agents thérapeutiques et découverte de médicaments associée à la macropinocytose
MX2015015601A (es) Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1).
Chen et al. MiRNA signatures in nasopharyngeal carcinoma: molecular mechanisms and therapeutic perspectives
Juneja et al. MicroRNAs and noncoding RNAs as gene regulators and potential therapeutic agents
WO2014005153A3 (fr) Procédés pour le traitement d'un cancer médié par la protéine mds1-evi1

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380042546.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13827192

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2015526754

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013827192

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13827192

Country of ref document: EP

Kind code of ref document: A2